Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer

Interim Analysis of Phase 2 Clinical Data Published at the American Society of Clinical Oncology 43rd Annual Meeting

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today released interim findings from its Phase II, multi-center clinical study of Amrubicin, the company's third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. These findings indicate favorable interim results in terms of response rate and safety when comparing Amrubicin to the current treatment standard, topotecan, in second-line treatment of platinum-sensitive small-cell lung cancer patients with extensive disease (ED-SCLC). The early results of this study were published online on the ASCO website during the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. (June 1- 5, 2007).

"Oncologists have very limited treatment options available for patients with extensive-disease small cell lung cancer, and regrettably, patients with this disease still have an exceptionally poor prognosis," said Andrew R. Allen, chief medical officer of Pharmion. "We are encouraged by these initial results which suggest Amrubicin's potential to improve the treatment landscape for small cell lung cancer."

The trial compares Amrubicin and topotecan in patients with ED-SCLC that initially responded to first-line platinum-based therapy but recurred or progressed at least 90 days after completion of first-line treatment. Study participants are randomized 2:1 to receive either Amrubicin (40 mg/m2 via 5- min.infusion daily x 3 days) or topotecan (1.5 mg/m2 via 30-min. infusion daily x 5 days), both starting on Day 1 of a 21-day cycle.

Response data from 24 evaluable patients have been analyzed, 15 treated with Amrubicin and nine with topotecan. Of the 15 Amrubicin patients, 40 percent showed an objective tumor response, including two complete r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Feb. 24, 2011 GlaxoSmithKline (GSK), one of ... 2010 Environmental Stewardship Award from Nalco Company (NYSE: ... ongoing efforts to reduce its climate change impact ... http://photos.prnewswire.com/prnh/20101231/NALCOLOGO ) The Environmental Stewardship ...
... N.C., Feb. 24, 2011 Chimerix, Inc., a pharmaceutical ... announced today that Kenneth I. Moch, President and Chief ... Health Care Conference on March 1, 2011 at 3:00 ... New York City, NY. Mr. Moch will ...
Cached Medicine Technology:GlaxoSmithKline Wins Environmental Stewardship Award 2GlaxoSmithKline Wins Environmental Stewardship Award 3Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Calif., Oct. 10 AlphaDetail, Inc., a leader,in primary ... Life Sciences Industry, continues to affirm its commitment to ... on the east coast. AlphaDetail will open a ... This will benefit a large number of clients located ...
... Oct. 10 The Pennsylvania,Department of Health today ... (CDC) advisory for consumers not to eat Banquet ... due to possible,Salmonella contamination., "Federal officials have ... want to ensure Pennsylvanians are taking the,appropriate measures ...
... Inc. (OTC,Bulletin Board: SCIE) announced today that it ... Company,s quality system from the Notified,Body G-MED. SpectraScience ... II.3 of the European directive 93/42/EEC. In addition, ... Jim Hitchin the Company,s CEO said, "This certification ...
... 10 Good Shepherd,Rehabilitation Network has expanded ... The virtual store at, http://www.rehabilitystores.com with ... of secure online shopping specifically for those ... and their caregivers., "Rehability offers a ...
... Rural/Metro,Corporation announced that a majority of its ... Capital Management LLC, the Company,s,largest stockholder. During the ... and constructive dialogue. The Board,s desire is to ... remains committed,to doing what is best to enhance ...
... likely to develop breathing problems, study finds, , , WEDNESDAY, Oct. ... in their first month of life were more likely to ... a new study found. , Danish researchers found that infants ... influenzae or Moraxella catarrhalis bacteria had more ...
Cached Medicine News:Health News:AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:SpectraScience Receives Final European Certification 2Health News:Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 3Health News:Early Bacterial Infection May Boost Asthma Risk 2Health News:Early Bacterial Infection May Boost Asthma Risk 3
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... Powerful, flexible, and fast, the ... combines leading edge technologies with user-oriented ... The integrated SONO MR package consists ... and control, including HI COMPOUND multi-angle ...
Medicine Products: